環保專案成果報告查詢系統

水中醫藥類及其代謝之殘留化學物質之檢測技術建立研究(4/4)

專案計畫編號	EPA-99-E3S4-02-01
經費年度	099
計畫經費	1,482 千元
專案開始日期	2010/01/01
專案結束日期	2010/12/31
專案主持人	林郁真
主辦單位	環檢所
承辦人	趙春美
執行單位	國立臺灣大學嚴慶齡工業發展基金會合設工業研究中心
專案分類	環境監測及檢測
中文關鍵字	藥物和個人保健用品;固相萃取法;液相層析串聯式質譜儀
英文關鍵字	Parmaceuticals and personal care products (PPCPs);Solid-phase extraction;LC/MS/MS
協同主持人
共同主持人	林正芳
計畫聯絡人	余宗賢
計畫聯絡電話	02-33664402#
計畫聯絡信箱	d95541004@ntu.edu.tw

中文摘要	本期末報告延續去年成果，蒐集彙整抗生素、β受體阻滯劑及β促效藥等醫藥類化學物質在水體環境中之分佈情形、生物毒性、及其可能對環境造成之衝擊等文獻資料。另調查統計國內中央健康保險局其奎諾酮類抗生素及咪唑類抗生素之使用量。於檢測技術建立方面，本工作團隊針對奎諾酮類抗生素及咪唑類抗生素(含nalidixic acid、flumequine、pipemidic acid、norfloxacin、ciprofloxacin、ofloxacin、dimetridazole及metronidazole等8種)進行LC/MS/MS分析方法建立，包含固相萃取方法、LC分析條件、MRM離子對選定及其質譜參數、檢測方法確效(檢量線配製、回收率測試、基質測試、方法偵測極限等)。回收率(濃度為50 ng/L)結果顯示，去離子水及空白水樣中奎諾酮類抗生素及咪唑類抗生素的回收率分別介於92.5~107.3%及87.8~118.9%之間；方法偵測極限(MDL)去離子水及空白水樣中測試結果均介於0.5~1.0 ng/L之間。本工作團隊另運用本年度及96~98年度之分析檢測方法，檢測調查中部地區六條河川流域中34種抗生素、4種β受體阻滯劑及4種β促效藥等醫藥類化合物之含量。河川水體之檢測結果，濃度範圍與國內外文獻相同，均介於ng/L-μg/L範圍。另就檢出頻率來看，以nalidixic acid (92%)、flumequine (79%)、metronidazole (96%)、sulfadiazine (96%)、sulfamethoxazole (100%)、sulfathiazole (88%)、sulfamethazine (92%)、lincomycin (88%)、clindamycin (83%)及erythromycin-H2O (83%)等醫藥類化合物之檢出頻率較高(檢出頻率>79%，總檢測樣品數為24件)。
中文關鍵字	藥物和個人保健用品;固相萃取法;液相層析串聯式質譜儀

中文摘要

本期末報告延續去年成果，蒐集彙整抗生素、β受體阻滯劑及β促效藥等醫藥類化學物質在水體環境中之分佈情形、生物毒性、及其可能對環境造成之衝擊等文獻資料。另調查統計國內中央健康保險局其奎諾酮類抗生素及咪唑類抗生素之使用量。於檢測技術建立方面，本工作團隊針對奎諾酮類抗生素及咪唑類抗生素(含nalidixic acid、flumequine、pipemidic acid、norfloxacin、ciprofloxacin、ofloxacin、dimetridazole及metronidazole等8種)進行LC/MS/MS分析方法建立，包含固相萃取方法、LC分析條件、MRM離子對選定及其質譜參數、檢測方法確效(檢量線配製、回收率測試、基質測試、方法偵測極限等)。回收率(濃度為50 ng/L)結果顯示，去離子水及空白水樣中奎諾酮類抗生素及咪唑類抗生素的回收率分別介於92.5~107.3%及87.8~118.9%之間；方法偵測極限(MDL)去離子水及空白水樣中測試結果均介於0.5~1.0 ng/L之間。本工作團隊另運用本年度及96~98年度之分析檢測方法，檢測調查中部地區六條河川流域中34種抗生素、4種β受體阻滯劑及4種β促效藥等醫藥類化合物之含量。河川水體之檢測結果，濃度範圍與國內外文獻相同，均介於ng/L-μg/L範圍。另就檢出頻率來看，以nalidixic acid (92%)、flumequine (79%)、metronidazole (96%)、sulfadiazine (96%)、sulfamethoxazole (100%)、sulfathiazole (88%)、sulfamethazine (92%)、lincomycin (88%)、clindamycin (83%)及erythromycin-H2O (83%)等醫藥類化合物之檢出頻率較高(檢出頻率>79%，總檢測樣品數為24件)。

中文關鍵字

藥物和個人保健用品;固相萃取法;液相層析串聯式質譜儀

類型	檔名	檔案大小	說明	最新版公開日期
期末報告	EPA-99-E3S4-02-01.pdf	6MB	EPA-99-E3S4-02-01期末報告	2011/2/1 上午 12:00:00

摘要	This final report has compiled the following specific information on PPCPs: (1) environmental occurrence, (2) toxicity/estrogenicity, (3) environmental risk assessment, (4) drug usage (including amount imported and used), (5) analytical method development grouping for coming projects. In addition, this report includes our analytical results on 6 selected quinolone antibiotics and 2 selected imidazole antibiotics, including LC and mass spec optimizing conditions and QA/QC (recovery test, matrix effect study, precision and accuracy, and method detection limit). The target compounds are nalidixic acid, flumequine, pipemidic acid, norfloxacin, ciprofloxacin, ofloxacin, dimetridazole and metronidazole. For recovery, DI water and real water were used as blanks, the recoveries range from 92.5-107.3% and 87.8-118.9%, respectively. The method detection limits (MDL) all are ranging from 0.5-1.0 ng/L in DI water and real water. Six rivers in Central Taiwan were examined using the established analytical methods including this year and last two year. Thirty-four antibiotics, 4 β-blockers and 4 β-agonists were detected in sample collected from six rivers. Based on analyzed data, concentrations of pharmaceuticals found were comparable to those detected around the world and were range from ng/L - μg/L. Nalidixic acid (92%), flumequine (79%), metronidazole (96%), sulfadiazine (96%), sulfamethoxazole (100%), sulfathiazole (88%), sulfamethazine (92%), lincomycin (88%), clindamycin (83%) and erythromycin-H2O (83%) were detected most frequently in all taken samples (frequency of detection >79%).
英文關鍵字	Parmaceuticals and personal care products (PPCPs);Solid-phase extraction;LC/MS/MS

摘要

This final report has compiled the following specific information on PPCPs: (1) environmental occurrence, (2) toxicity/estrogenicity, (3) environmental risk assessment, (4) drug usage (including amount imported and used), (5) analytical method development grouping for coming projects. In addition, this report includes our analytical results on 6 selected quinolone antibiotics and 2 selected imidazole antibiotics, including LC and mass spec optimizing conditions and QA/QC (recovery test, matrix effect study, precision and accuracy, and method detection limit). The target compounds are nalidixic acid, flumequine, pipemidic acid, norfloxacin, ciprofloxacin, ofloxacin, dimetridazole and metronidazole. For recovery, DI water and real water were used as blanks, the recoveries range from 92.5-107.3% and 87.8-118.9%, respectively. The method detection limits (MDL) all are ranging from 0.5-1.0 ng/L in DI water and real water. Six rivers in Central Taiwan were examined using the established analytical methods including this year and last two year. Thirty-four antibiotics, 4 β-blockers and 4 β-agonists were detected in sample collected from six rivers. Based on analyzed data, concentrations of pharmaceuticals found were comparable to those detected around the world and were range from ng/L - μg/L. Nalidixic acid (92%), flumequine (79%), metronidazole (96%), sulfadiazine (96%), sulfamethoxazole (100%), sulfathiazole (88%), sulfamethazine (92%), lincomycin (88%), clindamycin (83%) and erythromycin-H2O (83%) were detected most frequently in all taken samples (frequency of detection >79%).

英文關鍵字

Parmaceuticals and personal care products (PPCPs);Solid-phase extraction;LC/MS/MS

相關專案最新公開

水中醫藥類及其代謝之殘留化學物質...

生活污水中個人保健品殘留化學物質...

麟洛人工濕地排水水質改善工程後續...